Ranok Therapeutics Announces Positive Interim Phase 1 Data Of Its KRAS G12D Inhibitor RNK08954 In Patients With KRAS G12D-Mutated Metastatic Non-Small Cell Lung Cancer Presented At ASCO 2026
Clinically Meaningful Overall Antitumor Activity, with ORR of 42.9% and DCR of…
Eason Technology Announces the Formation of New Subsidiary, Four Ele Industrial Intelligent Tech to Target Power Energy, Energy Networks and New Energy Storage Facilities Scenarios
HONG KONG, June 1, 2026 /PRNewswire/ — Eason Technology Limited ("Eason" or…